Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals ...

A federal judge just invoked Star Trek in a $5 billion patent ruling against Moderna. Here is why the mRNA giant is heading ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most deadly ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials.

Jan 22 (Reuters) - Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to ...

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results are striking. The vaccine, paired with an immunotherapy drug, slashed the ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Add Yahoo as a preferred source to see more of our stories on Google. A nurse draws up doses of the Moderna COVID-19 for a vaccination clinic in St. Helena in 2021. Moderna is offering a new, low-dose ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b trial showed.